Regional immunity in melanoma: Immunosuppressive changes precede nodal metastasis

Modern Pathology

Volumn 24, Issue 4, 2011, Pages 487-494

  Mansfield, Aaron S ^a   Holtan, Shernan G ^a   Grotz, Travis E ^a   Allred, Jake B ^a   Jakub, James W ^a   Erickson, Lori A ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

angiogenesis; cytotoxic T cells; lymph nodes; melanoma; regional immunity

Indexed keywords

BIOLOGICAL MARKER; CD123 ANTIGEN; CD14 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GALECTIN 3; GLYCOPROTEIN; HLA DR ANTIGEN; HLA G ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; LYVE PROTEIN; OSTEOPONTIN; PLACENTAL GROWTH FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL POLARITY; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPH NODE; LYMPH NODE METASTASIS; LYMPH VESSEL; MALE; MELANOMA; MONOCYTE; PRIORITY JOURNAL; REGIONAL IMMUNITY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

ADULT; AGED; ANGIOGENIC PROTEINS; ANTIGENS, CD; CASE-CONTROL STUDIES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MELANOMA; MIDDLE AGED; MINNESOTA; MONOCYTES; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 79953303193     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.227     Document Type: Article

References (59)

1. Coit DG, Andtbacka R, Bichakjian CK, et al. Melanoma. J Natl Compr Canc Netw 2009;7:250-275.
2. Cochran AJ, Huang RR, Lee J, et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006;6:659-670. (Pubitemid 44298215)
3. Amersi F, Morton DL. The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg 2007;41:241-256.
4. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62-70. (Pubitemid 34779439)
5. Nevala WK, Vachon CM, Leontovich AA, et al. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009;15:1931-1939.
6. Farzad Z, Cochran AJ, McBride WH, et al. Lymphocyte subset alterations in nodes regional to human melanoma. Cancer Res 1990;50:3585-3588. (Pubitemid 20194099)
7. Negin B, Panka D, Wang W, et al. Effect of melanoma on immune function in the regional lymph node basin. Clin Cancer Res 2008;14:654-659. (Pubitemid 351231144)
8. Kohrt HE, Nouri N, Nowels K, et al. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005;2:e284.
9. Polak ME, Borthwick NJ, Gabriel FG, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007;96:1879-1887. (Pubitemid 46912012)
10. Jandus C, Bioley G, Speiser DE, et al. Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother 2008;57:1795-1805.
11. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453. (Pubitemid 38924326)
12. Mansfield AS, Heikkila PS, Vaara AT, et al. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 2009;9:231.
13. Matsuura K, Yamaguchi Y, Osaki A, et al. FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients. Oncol Rep 2009;22: 1181-1187.
14. Matsuura K, Yamaguchi Y, Ueno H, et al. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 2006;106:1227-1236. (Pubitemid 43363898)
15. Vence L, Palucka AK, Fay JW, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA 2007;104:20884-20889.
16. Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229: 152-172.
17. Berner V, Liu H, Zhou Q, et al. IFN-gamma mediates CD4+T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007;13:354-360. (Pubitemid 46376686)
18. Ugurel S, Uhlig D, Pfohler C, et al. Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother 2004;53:551-559. (Pubitemid 38680262)
19. Essner R, Kojima M. Dendritic cell function in sentinel nodes. Oncology (Williston Park) 2002;16:27-31.
20. Poindexter NJ, Sahin A, Hunt KK, et al. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 2004;6:R408-R415.
21. Cochran AJ, Morton DL, Stern S, et al. Sentinel lymph nodes show profound downregulation of antigenpresenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 2001;14: 604-608. (Pubitemid 32554086)
22. Gerlini G, Urso C, Mariotti G, et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol 2007; 125:184-193. (Pubitemid 47562900)
23. Lee JR, Dalton RR, Messina JL, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003;83: 1457-1466. (Pubitemid 37267829)
24. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-1274. (Pubitemid 37279849)
25. Movassagh M, Spatz A, Davoust J, et al. Selective accumulation of mature DC-Lamp+dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 2004;64:2192-2198. (Pubitemid 38339472)
26. Bembenek A, Li J, Loddenkemper C, et al. Presence of mature DC-Lamp+dendritic cells in sentinel and nonsentinel lymph nodes of breast cancer patients. Eur J Surg Oncol 2008;34:514-518. (Pubitemid 351514883)
27. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
28. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2: 573-583. (Pubitemid 37328924)
29. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007;34:555-565. (Pubitemid 350236307)
30. Achen MG, Stacker SA. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int J Cancer 2006;119:1755-1760. (Pubitemid 44356830)
31. Hirakawa S, Brown LF, Kodama S, et al. VEGF-Cinduced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007;109:1010-1017. (Pubitemid 46220646)
32. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005;201:1089-1099. (Pubitemid 40524677)
33. Mohammed RA, Green A, El-Shikh S, et al. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio-and lymphangiogenesis. Br J Cancer 2007;96:1092-1100. (Pubitemid 46608319)
34. van Iterson V, Leidenius M, von Smitten K, et al. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am J Clin Pathol 2007;128:759-766. (Pubitemid 350133986)
35. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005;18: 1232-1242. (Pubitemid 43079923)
36. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951-1960. (Pubitemid 36613052)
37. Massi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol 2006;59:166-173. (Pubitemid 43235582)
38. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-198. (Pubitemid 32148486)
39. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001;159: 893-903. (Pubitemid 32847180)
40. Boone B, Blokx W, De Bacquer D, et al. The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch 2008;453:257-265.
41. Sica A, Schioppa T, Mantovani A, et al. Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42: 717-727.
42. Holtan SG, Creedon DJ, Haluska P, et al. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 2009;84:985-1000.
43. Weber GF. Molecular mechanisms of metastasis. Cancer Lett 2008;270:181-190.
44. Allan AL, George R, Vantyghem SA, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006;169: 233-246.
45. Mourad-Zeidan AA, Melnikova VO, Wang H, et al. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 2008;173: 1839-1852.
46. Vereecken P, Awada A, Suciu S, et al. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 2009;19:316-320.
47. Botella-Estrada R, Dasi F, Ramos D, et al. Cytokine expression and dendritic cell density in melanoma sentinel nodes. Melanoma Res 2005;15:99-106. (Pubitemid 40637987)
48. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
49. Nagorsen D, Fetsch PA, Abati A, et al. Degree of CD14 expression in melanoma infiltrating mononuclear phagocytes. J Dermatol Sci 2005;37:52-54. (Pubitemid 40037579)
50. Shi J, Ikeda K, Maeda Y, et al. Identification of CD123+myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential. Cancer Lett 2008;270:19-29.
51. Lotem M, Zhao Y, Riley J, et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J Immunother 2006;29: 616-627. (Pubitemid 44674045)
52. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymphspecific receptor for hyaluronan. J Cell Biol 1999;144: 789-801. (Pubitemid 29234556)
53. Kang KH, Im SH. Differential regulation of the IL-10 gene in Th1 and Th2 T cells. Ann NY Acad Sci 2005; 1050:97-107.
54. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBOJ 1996;15:1751. (Pubitemid 26112397)
55. Oh SJ, Jeltsch MM, Birkenhager R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997;188:96-109. (Pubitemid 27360090)
56. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-352. (Pubitemid 41716771)
57. Jenner RG, Townsend MJ, Jackson I, et al. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. Proc Natl Acad Sci USA 2009;106:17876-17881.
58. Loges S, Roncal C, Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost 2009;7:21-33.
59. Hunt JS, Langat DK, McIntire RH, et al. The role of HLA-G in human pregnancy. Reprod Biol Endocrinol 2006;4(Suppl 1):S10.